// App-Quantinova.ai

434 : Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.

Researchers

Presenter

  • Matt D. Galsky

Principal Investigators

  • Jose Angel Arranz Arija

  • Ian D. Davis

  • Maria De Santis

  • Eiji Kikuchi

  • Xavier Garcia del Muro

  • Se Hoon Park

  • Ugo De Giorgi

  • Boris Alekseev

  • Marina Mencinger

  • Kouji Izumi

  • Javier Puente

  • Jian-Ri Li

  • Almut Mecke

  • Sanjeev Mariathasan

  • Romain Banchereau

  • Xinhui Huang

  • Chooi Peng Lee

  • Enrique Grande

Medical Centers

  • Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY

  • National and Kapodistrian University of Athens, Athens, Greece

  • Gregorio Maranon Hospital, Madrid, Spain

  • Eastern Health Clinical School, Monash University, Box Hill, VIC, Australia

  • Department of Urology, Charité University Hospital, Berlin, Germany and Department of Urology, Medical University of Vienna, Vienna, Austria

  • St.Marianna University School of Medcine, Kawasaki, Japan

  • Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, Spain

  • Samsung Medical Center, Seoul, Korea

  • Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

  • Research Oncology Institute, Tomsk, Russian Federation

  • Institute of Oncology Ljubljana, Ljubljana, Slovenia

  • Kanazawa University, Kanazawa, Japan

  • Hospital Clinico San Carlos, Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos (IdISSC), Madrid, Spain

  • Taichung Veterans General Hospital, Taichung City, Taiwan

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Genentech, Inc., South San Francisico, CA

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • GEICO & MD Anderson Cancer Center Madrid, Madrid, Spain

Locations

  • United States

  • Greece

  • Spain

  • Australia

  • Austria

  • Japan

  • Republic of South Korea

  • Italy

  • Russia

  • Slovenia

  • Taiwan

  • Switzerland

  • United Kingdom

Companies

  • F. Hoffmann-La Roche

  • Genentech, Inc.

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Atezolizumab

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02807636

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved